Anbio Biotechnology (NNNN) Q4 2025 earnings summary

Executive summary

• Revenue for 2025 was $8.65 million, up 5.6% from 2024, with gross profit of $7.54 million and net income of $6.40 million, reflecting a significant shift to non-COVID IVD products (80.4% of revenue in 2025).

• Gross margin improved to 87.2% in 2025 from 71.9% in 2024, driven by a higher-margin product mix and cost controls.

• The company completed its IPO in February 2025, raising $8 million in gross proceeds.

• Operations are primarily conducted through a Samoa subsidiary, with a global sales footprint and a focus on regulatory compliance for IVD products.

Financial highlights

• Revenue: $8.65M (2025), $8.19M (2024), $6.71M (2023); 2025 revenue up 5.6% YoY, 2024 up 21.9% YoY.

• Gross profit: $7.54M (2025), $5.89M (2024), $3.36M (2023); gross margin rose to 87.2% in 2025.

• Net income: $6.40M (2025), $2.37M (2024), $2.25M (2023); net income up 169.9% YoY in 2025.

• SG&A expenses dropped 54% in 2025 due to lower professional fees post-IPO and cost controls.

• R&D expenses decreased to $201K in 2025 as products matured and required less development.

• Cash and equivalents at year-end 2025: $7.77M; working capital: $30.16M.

Outlook and guidance

• Management expects continued growth in non-COVID IVD products and further market expansion.

• Focus on regulatory approvals (IVDR in EU, FDA in US) and diversification into new diagnostic segments.

• Sufficient cash and IPO proceeds to fund operations and expansion for at least 12 months.